Le Lézard
Classified in: Health
Subjects: SVY, TRI

Key Opinion Leads weigh in on Nutrafol® Proprietary Formula Published in the Journal of Drugs and Dermatology


NEW YORK, Feb. 21, 2018 /PRNewswire/ -- Key opinion leaders in the field of dermatology and hair loss published the first peer-reviewed article validating Nutrafol's approach to healthy hair growth. The article appeared in the November issue of the Journal of Drugs and Dermatology (JDD), a highly respected resource for dermatologists and researchers worldwide.

"As scientific research reveals more about hair follicle biology, we are compelled to look at the common thread within all hair disorders?the complex dysregulation of immune, inflammation and signaling cascades that regulate follicle homeostasis," says Sophia Kogan, MD, Chief Medical Officer, Nutrafol.  "We're thrilled to have the medical communities support as we continue to research drug-free solutions that not only help stimulate healthy hair growth but also improves one's overall health."

"Any therapeutic that targets singular triggers, such as androgens, without considering the pleiotropic downstream effects and the interplay of various signaling molecules ? is destined to be incomplete," adds Dr. Valerie Callender, Board-Certified Dermatologist. "We're thrilled to find a solution that not only stimulates hair growth but also improves one's overall health."

"We understand there are many factors that contribute to hair loss," says Roland Peralta, President and co-founder of Nutrafol®. "By remaining on the forefront of research and biotechnology, we are able to create a product that targets many of those factors with an exclusive formula that addresses those many triggers. We are honored to have such respected physicians partner with us to validate and share this new way of thinking to help millions of men and women who are in search of healthy hair growth solutions.

To date, Nutrafol has invested over one-third of its budget and investment from Unilever Ventures on research and innovation.  It is the brand's mission to offer customers a safe, healthy, drug free solution to help men and women optimize hair health.

For access to the full article click here

Media Contacts
Michelle Sabari Wrubel
Email: [email protected]

About Nutrafol®:
Frustrated by poor results and undesirable side effects from a leading pharmaceutical drug, Nutrafol's co-founders challenged the science behind conventional hair loss solutions. In 2015 they teamed up with world-renowned hair loss experts in the field of dermatology and integrative healthcare to develop a nutraceutical hair growth supplement composed of clinically -tested ingredients. With continued investment in research and clinical studies, Nutrafol® is poised to take the lead in the fragmented multibillion dollar global hair loss industry.

Nutrafol® is a science based research and development company focused on formulating hair health solutions.  Nutrafol® products for men and women are available through multiple channels including physicians, salons and online. The company is committed to providing natural, healthy and effective solutions for hair loss and poor hair health. For further information, please visit: www.nutrafol.com and follow the brand @Nutrafol on Facebook and Instagram.

 (PRNewsfoto/Nutrafol)

SOURCE Nutrafol


These press releases may also interest you

at 07:35
Endeavor BioMedicines, Inc. ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the closing of a $132.5...

at 07:30
BioArctic AB's (publ) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2024, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 2.83 billion were recorded in the...

at 07:25
RxLightning, creator of the industry's leading platform for streamlining specialty medication access and affordability, is proud to have reached a number of meaningful milestones in the last year ? including significant increases in provider users,...

at 07:12
Highlights from Chiesi Group's 2023 financial report: Sales increased to over ?3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions24% of 2023 sales...

at 07:05
Av?sis and Harmony Health have joined forces to bridge oral healthcare gaps for underserved Medicaid populations with special healthcare needs. The pilot aims to revolutionize preventive dentistry by harnessing the power of real-time salivary testing...

at 07:05
United Therapeutics Corporation , announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately...



News published on and distributed by: